Did you know?
You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)
"I would appreciate Mark Day, JD or others providing a reminder of the advantages of xB3 over Angiopep-2, especially in light of them both being LRP-1 receptor ligands. Why has Angiochem stalled? What differentiates xB3 from Angiopep-2?"
